A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting

Current Medical Research and Opinion

Volumn 28, Issue 7, 2012, Pages 1155-1162

  Guérin, Annie ^a   Chen, Lei ^b   Wu, Eric Q ^a   Ponce De Leon, Diego ^a   Griffin, James D ^c  

^a ANALYSIS GROUP   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adherence; Chronic myeloid leukemia; Second line; Tyrosine kinase inhibitor

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB;

ADULT; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY ANALYSIS; TREATMENT DURATION; UNITED STATES;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RETROSPECTIVE STUDIES; THIAZOLES;

EID: 84863618702     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.705264     Document Type: Review

References (19)

1. Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med (1999);131:207-19 (Pubitemid 29365004)
2. Altekruse S, Kosary CL, Krapcho M et al. SEER Cancer Statistics Review. 2011. Available at: http://seer.cancer.gov/csr/1975-2007/[Last accessed 25 January 2012]
3. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood (2010);116:3758-65
4. ELN. Recommendations from the European LeukemiaNet for the Management of chronic myeloid leukemia (CML). Available at: http://www.leukemianet. org/content/leukemias/cml/recommendations/[Last accessed 25 January 2012]
5. NCCN. NCCN Guidelines Version 2.2011-Chronic Myelogenous Leukemia. NCCN Guidelines, 2011
6. US Food and Drug Administration: Dasatinib. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2011/021986s009s010lbl.pdf [Last accessed 9 May 2012]
7. Julius RJ, Novitsky Jr MA, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract (2009); 15:34-44
8. US Food and Drug Administration: Nilotinib. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2012/022068s012lbl.pdf [Last accessed 9 May 2012]
9. Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood (2009);113:5401-11
10. Doti C, Stemmelin G, Shanley C, et al. Cytogenetic response in relation to the adherence to treatment with imatinib mesylate: a case control study. Blood (ASH Annual Meeting Abstracts) (2007);110: Abstract 4553
11. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol (2010);28:2381-8
12. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy. Blood (2011);10:3733-6
13. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med (2010);362:2260-70
14. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med (2010);362: 2251-9
15. Yood MU, Oliveria SA, Cziraky M, et al. Adherence to treatment with secondline therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin (2012);28:213-19
16. Wu EQ, Guerin A, Yu AP, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin (2010);26:2861-9
17. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and nonadherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics (2007);25:481-96 (Pubitemid 46849189)
18. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health (2007);10:3-12 (Pubitemid 46161090)
19. Santos FPS, Kantarjian H, Fava C, et al. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol (2010);150:303-12